サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：セフトリアキソンの世界市場：適応症別 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
市場調査レポート
商品コード
1208548

セフトリアキソンの世界市場：適応症別 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Ceftriaxone Market (Indication: Urinary Tract Infections, Intra-abdominal Infections, Endocarditis, Acute Bacterial Otitis Media, Meningitis, Pneumonia, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 170 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
セフトリアキソンの世界市場：適応症別 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年12月14日
発行: Transparency Market Research
ページ情報: 英文 170 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のセフトリアキソン市場について調査分析し、市場動向、セグメント分析、地域分析、企業プロファイルなどを提供しています。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー

  • 市場の概要
  • イントロダクション

第4章 市場力学

  • 促進要因
  • 抑制要因
  • 機会
  • 世界のセフトリアキソン市場の予測
  • 世界のセフトリアキソン市場の見通し

第5章 市場の見通し

  • 主な市場の動向
  • 規制シナリオ：地域別
  • 業界に対するCOVID-19パンデミックの影響（バリューチェーンと短/中/長期の影響）

第6章 世界のセフトリアキソン市場の分析と予測：適応症別

  • イントロダクション
  • 世界のセフトリアキソンの市場金額シェアと魅力分析：適応症別
  • 世界のセフトリアキソン市場の予測：適応症別
    • 尿路感染症
    • 腹腔内感染症
    • 心内膜炎
    • 急性細菌性中耳炎
    • 髄膜炎
    • 肺炎
    • その他

第7章 世界のセフトリアキソン市場の分析と予測：流通チャネル別

  • イントロダクション
  • 世界のセフトリアキソンの市場金額シェア分析：流通チャネル別
  • 世界のセフトリアキソン市場の予測：流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 世界のセフトリアキソン市場の分析：流通チャネル別

第8章 世界のセフトリアキソン市場の分析：地域別

  • 世界のセフトリアキソン市場の分析：地域別
  • 世界のセフトリアキソンの市場金額シェアと魅力分析：地域別
  • 世界のセフトリアキソン市場の予測：地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ

第9章 北米のセフトリアキソン市場の分析

  • 北米のセフトリアキソン市場の概要
  • 北米のセフトリアキソンの市場金額シェアと魅力分析：国別
  • 北米のセフトリアキソン市場の予測：国別
    • 米国
    • カナダ
  • 北米のセフトリアキソンの市場金額シェアと魅力分析：適応症別
  • 北米のセフトリアキソン市場の予測：適応症別
  • 北米のセフトリアキソンの市場金額シェアと魅力分析：流通チャネル別
  • 北米のセフトリアキソン市場の予測：流通チャネル別

第10章 欧州のセフトリアキソン市場の分析

第11章 アジア太平洋のセフトリアキソン市場の分析

第12章 ラテンアメリカのセフトリアキソン市場の分析

第13章 中東・アフリカのセフトリアキソン市場の分析

第14章 競合分析

  • 競合マトリックス
  • 市場シェア分析：企業別（2021年）
  • 企業プロファイル
    • Hikma Pharmaceuticals plc
    • Qilu Pharmaceutical Co. Ltd.
    • Novartis AG
    • Baxter International, Inc.
    • Aurobindo Pharma
    • ACS DOBFAR S.P.A.
    • Orchid Pharma
    • Nectar Lifesciences Ltd.
    • Lupin Pharmaceuticals, Inc.
図表

List of Tables

  • Table 01: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 02: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 05: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 06: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 07: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 08: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 09: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 10: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 11: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 12: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 15: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 18: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 02: Global Ceftriaxone Market Value Share, by Indication (2021)
  • Figure 03: Global Ceftriaxone Market Value Share, by Distribution Channel (2021)
  • Figure 04: Global Ceftriaxone Market Value Share, by Region (2021)
  • Figure 05: Global Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 06: Global Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 07: Global Ceftriaxone Market Revenue (US$ Mn), by Urinary Tract Infections, 2017-2031
  • Figure 08: Global Ceftriaxone Market Revenue (US$ Mn), by Intra-abdominal Infections, 2017-2031
  • Figure 09: Global Ceftriaxone Market Revenue (US$ Mn), by Endocarditis, 2017-2031
  • Figure 10: Global Ceftriaxone Market Revenue (US$ Mn), by Acute Bacterial Otitis Media, 2017-2031
  • Figure 11: Global Ceftriaxone Market Revenue (US$ Mn), by Meningitis, 2017-2031
  • Figure 12: Global Ceftriaxone Market Revenue (US$ Mn), by Pneumonia, 2017-2031
  • Figure 13: Global Ceftriaxone Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 14: Global Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 15: Global Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 16: Global Ceftriaxone Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 17: Global Ceftriaxone Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 18: Global Ceftriaxone Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 19: Global Ceftriaxone Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 20: Global Ceftriaxone Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 21: North America Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 22: North America Ceftriaxone Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 23: North America Ceftriaxone Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 24: North America Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 25: North America Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 26: North America Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 27: North America Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 28: Europe Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 29: Europe Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 30: Europe Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 31: Europe Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 32: Europe Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 33: Europe Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 34: Europe Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 35: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 36: Asia Pacific Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 37: Asia Pacific Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 38: Asia Pacific Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 39: Asia Pacific Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 40: Asia Pacific Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 41: Asia Pacific Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Latin America Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 43: Latin America Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 44: Latin America Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 45: Latin America Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 46: Latin America Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 47: Latin America Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 48: Latin America Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 49: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 50: Middle East & Africa Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 51: Middle East & Africa Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 52: Middle East & Africa Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
  • Figure 53: Middle East & Africa Ceftriaxone Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 54: Middle East & Africa Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 55: Middle East & Africa Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 56: Global Ceftriaxone Market Share, by Company, 2021
目次
Product Code: TMRGL85274

The report provides revenue of the global ceftriaxone market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ceftriaxone market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the ceftriaxone market.

The report delves into the competitive landscape of the global ceftriaxone market. Key players operating in the global ceftriaxone market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ceftriaxone market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Assumptions and Acronyms Used
  • 2.2. Research Methodology

3. Executive Summary

  • 3.1. Market Overview
  • 3.2. Introduction

4. Market Dynamics

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Opportunity
  • 4.4. Global Ceftriaxone Market Forecast
  • 4.5. Global Ceftriaxone Market Outlook

5. Market Outlook

  • 5.1. Key Market Trends
  • 5.2. Regulatory Scenario, by Region
  • 5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Ceftriaxone Market Analysis and Forecast, by Indication

  • 6.1. Introduction
  • 6.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 6.3. Global Ceftriaxone Market Forecast, by Indication
    • 6.3.1. Urinary Tract Infections
    • 6.3.2. Intra-abdominal Infections
    • 6.3.3. Endocarditis
    • 6.3.4. Acute Bacterial Otitis Media
    • 6.3.5. Meningitis
    • 6.3.6. Pneumonia
    • 6.3.7. Others

7. Global Ceftriaxone Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Global Ceftriaxone Market Value Share Analysis, by Distribution Channel
  • 7.3. Global Ceftriaxone Market Forecast, by Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Global Ceftriaxone Market Analysis, by Distribution Channel

8. Global Ceftriaxone Market Analysis, by Region

  • 8.1. Global Ceftriaxone Market Analysis, by Region
  • 8.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Region
  • 8.3. Global Ceftriaxone Market Forecast, by Region
    • 8.3.1. North America
    • 8.3.2. Europe
    • 8.3.3. Asia Pacific
    • 8.3.4. Latin America
    • 8.3.5. Middle East & Africa

9. North America Ceftriaxone Market Analysis

  • 9.1. North America Ceftriaxone Market Overview
  • 9.2. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country
  • 9.3. North America Ceftriaxone Market Forecast, by Country
    • 9.3.1. U.S.
    • 9.3.2. Canada
  • 9.4. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 9.5. North America Ceftriaxone Market Forecast, by Indication
    • 9.5.1. Urinary Tract Infections
    • 9.5.2. Intra-abdominal Infections
    • 9.5.3. Endocarditis
    • 9.5.4. Acute Bacterial Otitis Media
    • 9.5.5. Meningitis
    • 9.5.6. Pneumonia
    • 9.5.7. Others
  • 9.6. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 9.7. North America Ceftriaxone Market Forecast, by Distribution Channel
    • 9.7.1. Hospital Pharmacies
    • 9.7.2. Retail Pharmacies
    • 9.7.3. Online Pharmacies

10. Europe Ceftriaxone Market Analysis

  • 10.1. Europe Ceftriaxone Market Overview
  • 10.2. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 10.3. Europe Ceftriaxone Market Forecast, by Country/Sub-region
    • 10.3.1. Germany
    • 10.3.2. U.K.
    • 10.3.3. France
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Rest of Europe
  • 10.4. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 10.5. Europe Ceftriaxone Market Forecast, by Indication
    • 10.5.1. Urinary Tract Infections
    • 10.5.2. Intra-abdominal Infections
    • 10.5.3. Endocarditis
    • 10.5.4. Acute Bacterial Otitis Media
    • 10.5.5. Meningitis
    • 10.5.6. Pneumonia
    • 10.5.7. Others
  • 10.6. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 10.7. Europe Ceftriaxone Market Forecast, by Distribution Channel
    • 10.7.1. Hospital Pharmacies
    • 10.7.2. Retail Pharmacies
    • 10.7.3. Online Pharmacies

11. Asia Pacific Ceftriaxone Market Analysis

  • 11.1. Asia Pacific Ceftriaxone Market Overview
  • 11.2. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 11.3. Asia Pacific Ceftriaxone Market Forecast, by Country/Sub-region
    • 11.3.1. China
    • 11.3.2. India
    • 11.3.3. Japan
    • 11.3.4. Australia & New Zealand
    • 11.3.5. Rest of Asia Pacific
  • 11.4. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 11.5. Asia Pacific Ceftriaxone Market Forecast, by Indication
    • 11.5.1. Urinary Tract Infections
    • 11.5.2. Intra-abdominal Infections
    • 11.5.3. Endocarditis
    • 11.5.4. Acute Bacterial Otitis Media
    • 11.5.5. Meningitis
    • 11.5.6. Pneumonia
    • 11.5.7. Others
  • 11.6. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 11.7. Asia Pacific Ceftriaxone Market Forecast, by Distribution Channel
    • 11.7.1. Hospital Pharmacies
    • 11.7.2. Retail Pharmacies
    • 11.7.3. Online Pharmacies

12. Latin America Ceftriaxone Market Analysis

  • 12.1. Latin America Ceftriaxone Market Overview
  • 12.2. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 12.3. Latin America Ceftriaxone Market Forecast, by Country/Sub-region
    • 12.3.1. Brazil
    • 12.3.2. Mexico
    • 12.3.3. Rest of Latin America
  • 12.4. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 12.5. Latin America Ceftriaxone Market Forecast, by Indication
    • 12.5.1. Urinary Tract Infections
    • 12.5.2. Intra-abdominal Infections
    • 12.5.3. Endocarditis
    • 12.5.4. Acute Bacterial Otitis Media
    • 12.5.5. Meningitis
    • 12.5.6. Pneumonia
    • 12.5.7. Others
  • 12.6. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 12.7. Latin America Ceftriaxone Market Forecast, by Distribution Channel
    • 12.7.1. Hospital Pharmacies
    • 12.7.2. Retail Pharmacies
    • 12.7.3. Online Pharmacies

13. Middle East & Africa Ceftriaxone Market Analysis

  • 13.1. Middle East & Africa Ceftriaxone Market Overview
  • 13.2. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
  • 13.3. Middle East & Africa Ceftriaxone Market Forecast, by Country/Sub-region
    • 13.3.1. GCC Countries
    • 13.3.2. South Africa
    • 13.3.3. Rest of Middle East & Africa
  • 13.4. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
  • 13.5. Middle East & Africa Ceftriaxone Market Forecast, by Indication
    • 13.5.1. Urinary Tract Infections
    • 13.5.2. Intra-abdominal Infections
    • 13.5.3. Endocarditis
    • 13.5.4. Acute Bacterial Otitis Media
    • 13.5.5. Meningitis
    • 13.5.6. Pneumonia
    • 13.5.7. Others
  • 13.6. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 13.7. Middle East & Africa Ceftriaxone Market Forecast, by Distribution Channel
    • 13.7.1. Hospital Pharmacies
    • 13.7.2. Retail Pharmacies
    • 13.7.3. Online Pharmacies

14. Competitive Analysis

  • 14.1. Competition Matrix
  • 14.2. Market Share Analysis, by Company, 2021
  • 14.3. Company Profile
    • 14.3.1. Hikma Pharmaceuticals plc
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. Strategic Overview
      • 14.3.1.5. SWOT Analysis
    • 14.3.2. Qilu Pharmaceutical Co. Ltd.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. Strategic Overview
      • 14.3.2.5. SWOT Analysis
    • 14.3.3. Novartis AG
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. Strategic Overview
      • 14.3.3.5. SWOT Analysis
    • 14.3.4. Baxter International, Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. Strategic Overview
      • 14.3.4.5. SWOT Analysis
    • 14.3.5. Aurobindo Pharma
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Strategic Overview
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. ACS DOBFAR S.P.A.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Strategic Overview
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Orchid Pharma
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Strategic Overview
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Nectar Lifesciences Ltd.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. Strategic Overview
      • 14.3.8.5. SWOT Analysis
    • 14.3.9. Lupin Pharmaceuticals, Inc.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. Strategic Overview
      • 14.3.9.5. SWOT Analysis